<DOC>
	<DOCNO>NCT02781727</DOCNO>
	<brief_summary>A 52 week trial TransCon hGH , long-acting growth hormone product , versus human growth hormone therapy . TransCon hGH give once-a-week , human growth hormone ( hGH ) give daily . Approximately 150 prepubertal , hGH-treatment naïve child ( male female ) GHD include . Randomization occur 2:1 ratio ( TransCon hGH : Genotropin ) . This global trial conduct , limited , United States , Canada , Germany , France , Poland , Bulgaria , Russia Australia .</brief_summary>
	<brief_title>A Phase 3 Trial Safety , Tolerability Efficacy TransCon hGH Weekly Versus Daily hGH Children With Growth Hormone Deficiency ( GHD )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Prepubertal child GHD ( either isolate part multiple pituitary hormone deficiency ) Tanner stage 1 ( Tanner 1982 ) age : Boys : 312 year , inclusive Girls : 311 year , inclusive Impaired height ( HT ) define least 2.0 standard deviation ( SD ) mean height chronological age sex ( HT SDS ≤ 2.0 ) accord 2000 CDC Growth Charts United States Methods Development , available http : //www.cdc.gov/growthcharts/ Diagnosis GHD confirm 2 different GH stimulation test , define peak GH level ≤10 ng/mL , determine validate assay Bone age ( BA ) least 6 month less chronological age Baseline IGF1 level least 1 SD mean IGF1 level standardize age sex ( IGF1 SDS ≤1 ) Written , sign informed consent parent ( ) legal guardian ( ) subject write assent subject ( subject able read , understand , sign ) Children body weight 12 kg Prior exposure recombinant hGH IGF1 therapy Children past present intracranial tumor growth confirm sellar MRI scan ( contrast ) Screening ( MRI result 6 month prior Screening may accept ) Children psychosocial dwarfism Children idiopathic short stature History presence malignant disease ; evidence present tumor growth Closed epiphysis Major medical condition and/or presence contraindication hGH treatment Participation trial investigational agent within 3 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Human Growth Hormone</keyword>
	<keyword>hGH</keyword>
	<keyword>GHD</keyword>
	<keyword>rHGH</keyword>
	<keyword>Pediatric Growth Hormone Deficiency</keyword>
	<keyword>Long Acting Growth Hormone</keyword>
	<keyword>Somatropin</keyword>
	<keyword>Prodrug</keyword>
	<keyword>Growth Failure</keyword>
	<keyword>Growth Hormone Replacement Therapy</keyword>
	<keyword>Sustained Release</keyword>
	<keyword>Sustained Release Growth Hormone</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
</DOC>